No Data
Nikkei Average Contribution Ranking (Closing) ~ Nikkei Average continues to rise, with Fast Retailing and Advantest pushing up about 92 yen with 2 stocks.
At the closing time on the 4th, the number of rising stocks among the components of the Nikkei Average was 156, with 68 declining and 1 unchanged. On the 3rd, the Dow Jones Industrial Average in the US market closed at 42,011.59, down 184.93 points, while the Nasdaq ended trading at 17,918.48, down 6.64 points. Concerns over the escalation of the situation in the Middle East weighed on the market, but the ISM non-manufacturing business activity index rose more than expected, leading to an improvement in economic outlook and a temporary return to positive territory. However, President Biden's Israel...
Today's flows: 10/03 Lasertec saw an inflow of JPY¥ 11.7 billion, Tokyo Electron saw an outflow of JPY¥ 8.33 billion
On October 3rd, the TSE Main Market saw an inflow of JPY¥ 803 billion and an outflow of JPY¥ 795.98 billion.$Lasertec(6920.JP)$, $Fast Retailing(9983.JP)$ and $Advantest(6857.JP)$ were net buyers of
The afternoon Nikkei average started 862 yen higher with companies like Tokio Marine and Daiichi Sankyo trading higher.
[Nikkei Stock Average・TOPIX (Table)] Nikkei Stock Average; 38,671.23; +862.47 TOPIX; 2,691.34; +39.38 [Afternoon Summary] The afternoon Nikkei average started at 38,671.23 yen, up 862.47 yen from the previous day, almost the same level as the morning close (38,655.03 yen). During lunchtime, the Nikkei 225 futures traded in the range of 38,640 yen to 38,740 yen. The dollar-yen exchange rate is around 1 dollar = 146.80-90 yen, down about 30 ticks from around 9:00 a.m.
Express News | Esperion Therapeutics Shares Are Trading Higher After the Company Announced That Its European Partner, Daiichi Sankyo Europe, Reported Final 2-year Follow-up Data From the German Cohort of the Multinational, European Observational MILOS Study
AstraZeneca's Enhertu Application Accepted by FDA With Priority Review
ENHERTU (Fam-trastuzumab Deruxtecan-nxki) Granted Priority Review in the US for Patients With HER2-low or HER2-ultralow Metastatic Breast Cancer Who Have Received at Least One Line of Endocrine Therapy
No Data
No Data
No Data
